Vertex's triple CF combo meets in Phase III

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said one of its two cystic fibrosis triple combination therapies has met the primary endpoint of improving lung function in two Phase III trials. The company’s triple regimens have the potential to address about 90% of the CF market.

In one study, VX-659 plus tezacaftor and Kalydeco ivacaftor led to a mean absolute improvement in percent predicted forced expiratory volume in one second (ppFEV1) of 14 percentage points from baseline to week 4 vs. placebo (p<0.0001) among 380 evaluable patients with one ΔF508 mutation and one minimal function mutation...